Canada
· Delayed Price · Currency is CAD Optimind Pharma Statistics
Total Valuation
Optimind Pharma has a market cap or net worth of CAD 515,742. The enterprise value is 530,092.
| Market Cap | 515,742 |
| Enterprise Value | 530,092 |
Important Dates
The next estimated earnings date is Thursday, January 29, 2026.
| Earnings Date | Jan 29, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Optimind Pharma has 103.15 million shares outstanding. The number of shares has increased by 0.22% in one year.
| Current Share Class | 103.15M |
| Shares Outstanding | 103.15M |
| Shares Change (YoY) | +0.22% |
| Shares Change (QoQ) | -1.49% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | n/a |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 4.16 |
| PB Ratio | -6.43 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | 19.33 |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -11.31 |
| EV / Sales | 4.27 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.56
| Current Ratio | 0.56 |
| Quick Ratio | 0.56 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -9.85% |
| Return on Invested Capital (ROIC) | -33.09% |
| Return on Capital Employed (ROCE) | 44.75% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 0.58 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
| Beta (5Y) | 0.16 |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | 0.01 |
| 200-Day Moving Average | n/a |
| Relative Strength Index (RSI) | 45.97 |
| Average Volume (20 Days) | 18,580 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Optimind Pharma had revenue of CAD 124,012 and -46,877 in losses. Loss per share was -0.00.
| Revenue | 124,012 |
| Gross Profit | 77,781 |
| Operating Income | -33,631 |
| Pretax Income | -46,877 |
| Net Income | -46,877 |
| EBITDA | n/a |
| EBIT | -33,631 |
| Loss Per Share | -0.00 |
Balance Sheet
The company has 122,094 in cash and 120,637 in debt, giving a net cash position of 1,457 or 0.00 per share.
| Cash & Cash Equivalents | 122,094 |
| Total Debt | 120,637 |
| Net Cash | 1,457 |
| Net Cash Per Share | 0.00 |
| Equity (Book Value) | -80,159 |
| Book Value Per Share | -0.00 |
| Working Capital | -125,159 |
Cash Flow
| Operating Cash Flow | 26,684 |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
Gross margin is 62.72%, with operating and profit margins of -27.12% and -37.80%.
| Gross Margin | 62.72% |
| Operating Margin | -27.12% |
| Pretax Margin | -37.80% |
| Profit Margin | -37.80% |
| EBITDA Margin | n/a |
| EBIT Margin | -27.12% |
| FCF Margin | n/a |
Dividends & Yields
Optimind Pharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.22% |
| Shareholder Yield | -0.22% |
| Earnings Yield | -9.09% |
| FCF Yield | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Optimind Pharma has an Altman Z-Score of -33.26 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -33.26 |
| Piotroski F-Score | 3 |